Ziopharm announced that the FDA has granted fast track designation for its controlled IL-12 program, or Ad-RTS-hIL-12 plus veledimex, for the treatment of recurrent or progressive glioblastoma multiforme, or rGBM, in adults. Data previously presented suggest that Ad-RTS-hIL-12 with 20mg veledimex improves the median overall survival from six to nine months seen with available therapies to 12.7 months, with further improvement to 17.8 months in a subset of subjects with reduced cumulative steroid exposure during the active dosing period of veledimex.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.